Compare Stocks: BMRA, CUPR, NVST, and LUCYW

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BMRA Biomerica	$1.72 -1.1%	$2.06	$1.45 ▼ $2.94	$5.32M	0.38	11,820 shs	10,215 shs
CUPR Cuprina Holdings (Cayman)	$1.75 -4.9%	$2.30	$1.45 ▼ $14.80	$12.40M	-0.1	116,412 shs	11,785 shs
LUCYW Innovative Eyewear	$0.05 -2.0%	$0.04	$0.03 ▼ $0.12	N/A	N/A	10,255 shs	806 shs
NVST Envista	$23.48 -4.6%	$24.59	$18.77 ▼ $30.42	$3.78B	0.89	2.82 million shs	3.73 million shs

10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BMRA Biomerica	0.00%	+2.38%	-21.28%	+15.44%	-38.35%
CUPR Cuprina Holdings (Cayman)	0.00%	-5.41%	-31.37%	-40.07%	+174,999,900.00%
LUCYW Innovative Eyewear	0.00%	+71.38%	+18.00%	+27.30%	-39.68%
NVST Envista	0.00%	-0.57%	+1.45%	-14.27%	+17.55%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BMRA Biomerica	$1.72 -1.1%	$2.06	$1.45 ▼ $2.94	$5.32M	0.38	11,820 shs	10,215 shs
CUPR Cuprina Holdings (Cayman)	$1.75 -4.9%	$2.30	$1.45 ▼ $14.80	$12.40M	-0.1	116,412 shs	11,785 shs
LUCYW Innovative Eyewear	$0.05 -2.0%	$0.04	$0.03 ▼ $0.12	N/A	N/A	10,255 shs	806 shs
NVST Envista	$23.48 -4.6%	$24.59	$18.77 ▼ $30.42	$3.78B	0.89	2.82 million shs	3.73 million shs

10 Stocks Powering The Next AI Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BMRA Biomerica	0.00%	+2.38%	-21.28%	+15.44%	-38.35%
CUPR Cuprina Holdings (Cayman)	0.00%	-5.41%	-31.37%	-40.07%	+174,999,900.00%
LUCYW Innovative Eyewear	0.00%	+71.38%	+18.00%	+27.30%	-39.68%
NVST Envista	0.00%	-0.57%	+1.45%	-14.27%	+17.55%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BMRA Biomerica	1.00	Sell	$9.00	423.26% Upside
CUPR Cuprina Holdings (Cayman)	1.00	Sell	N/A	N/A
LUCYW Innovative Eyewear	0.00	N/A	N/A	N/A
NVST Envista	2.35	Hold	$28.86	22.90% Upside

Current Analyst Ratings Breakdown

Latest BMRA, CUPR, NVST, and LUCYW Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/15/2026	NVST Envista	Robert W. Baird Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Outperform ➝ Neutral	$34.00 ➝ $26.00
10/15/2026	NVST Envista	Robert W. Baird Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Outperform ➝ Neutral	$34.00 ➝ $26.00
10/14/2026	BMRA Biomerica	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (E+) ➝ Sell (D-)
10/14/2026	NVST Envista	Leerink Partners Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Outperform	$35.00 ➝ $32.00
10/13/2026	CUPR Cuprina Holdings (Cayman)	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Sell (D-) ➝ Sell (E+)
10/9/2026	NVST Envista	Piper Sandler Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Neutral	$28.00 ➝ $26.00
10/5/2026	NVST Envista	Zacks Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Strong-Buy ➝ Hold
9/28/2026	NVST Envista	BMO Capital Markets Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Market Perform	$29.00 ➝ $26.00
9/18/2026	NVST Envista	Piper Sandler Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Neutral	$28.00
9/18/2026	NVST Envista	UBS Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Neutral	$30.00 ➝ $27.00
9/18/2026	NVST Envista	Needham & Company LLC Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Hold

(Data available from 11/1/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BMRA Biomerica	$4.45M	1.19	N/A	N/A	$1.18 per share	1.46
CUPR Cuprina Holdings (Cayman)	$40K	306.25	N/A	N/A	$1.50 per share	1.17
LUCYW Innovative Eyewear	$3.41M	N/A	N/A	N/A	N/A	N/A
NVST Envista	$2.72B	1.39	$2.17 per share	10.83	$18.89 per share	1.24

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BMRA Biomerica	-$3.78M	-$1.64	N/A	N/A	N/A	-115.50%	-142.81%	-77.83%	1/8/2027 (Estimated)
CUPR Cuprina Holdings (Cayman)	-$3.63M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
LUCYW Innovative Eyewear	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	11/12/2026 (Estimated)
NVST Envista	$47M	$0.58	40.48	14.32	1.20	3.33%	7.88%	4.33%	11/4/2026 (Estimated)

Latest BMRA, CUPR, NVST, and LUCYW Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/12/2026	N/A	LUCYW Innovative Eyewear	-$0.35	N/A	N/A	N/A	$2.00 million	N/A
11/4/2026	Q3 2026	NVST Envista	$0.3561	N/A	N/A	N/A	$688.70 million	N/A
10/21/2026	Q1 2027	BMRA Biomerica	-$1.20	-$0.37	+$0.83	-$0.37	$3.63 million	$1.27 million
8/31/2026	Q4 2026	BMRA Biomerica	-$1.20	-$0.38	+$0.82	-$0.3690	$3.63 million	$0.88 million
8/5/2026	Q2 2026	NVST Envista	$0.3353	$0.41	+$0.0747	$0.33	$716.11 million	$730.50 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BMRA Biomerica	N/A	N/A	N/A	N/A	N/A
CUPR Cuprina Holdings (Cayman)	N/A	N/A	N/A	N/A	N/A
LUCYW Innovative Eyewear	N/A	N/A	N/A	N/A	N/A
NVST Envista	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BMRA Biomerica	N/A	1.91	1.33
CUPR Cuprina Holdings (Cayman)	N/A	N/A	N/A
LUCYW Innovative Eyewear	N/A	N/A	N/A
NVST Envista	0.47	2.43	2.07

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BMRA Biomerica	22.28%
CUPR Cuprina Holdings (Cayman)	N/A
LUCYW Innovative Eyewear	N/A
NVST Envista	N/A

Insider Ownership

Company	Insider Ownership
BMRA Biomerica	12.30%
CUPR Cuprina Holdings (Cayman)	N/A
LUCYW Innovative Eyewear	N/A
NVST Envista	0.99%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BMRA Biomerica	50	3.09 million	2.71 million	No Data
CUPR Cuprina Holdings (Cayman)	10	7.00 million	N/A	N/A
LUCYW Innovative Eyewear	13	N/A	N/A	Not Optionable
NVST Envista	12,000	160.62 million	159.03 million	Optionable

BMRA, CUPR, NVST, and LUCYW Headlines

Recent News About These Companies

Envista (NYSE:NVST) Shares Cross Below Fifty Day Moving Average - Here's Why

October 31 at 6:59 AM | marketbeat.com

Envista Q3 Earnings Ahead: Product Innovation to Drive Growth

October 28, 2026 | zacks.com

Envista (NVST) Earnings Expected to Grow: Should You Buy?

October 28, 2026 | zacks.com

Envista Holdings Corp

October 27, 2026 | 247wallst.com

Envista Announces Release of 2025 Sustainability Report

October 27, 2026 | prnewswire.com

Envista: Divergence Between Short-Term And Long-Term Prospects (Rating Downgrade)

October 22, 2026 | seekingalpha.com

Baird downgrades Envista Holdings to neutral from outperform

October 22, 2026 | msn.com

Envista (NYSE:NVST) Rating Lowered to "Hold" at Robert W. Baird

October 16, 2026 | marketbeat.com

Baird Downgrades Envista Holdings Corp. (NVST) to Neutral

October 15, 2026 | streetinsider.com

Baird Downgrades Envista Holdings to Neutral From Outperform, Price Target is $26

October 15, 2026 | marketscreener.comM

Envista Holdings Corporation (NYSE:NVST) Stock Rated "Hold" by Wall Street Brokerages

October 11, 2026 | marketbeat.com

Piper Sandler Issues Pessimistic Forecast for Envista (NYSE:NVST) Stock Price

October 9, 2026 | marketbeat.com

Envista (NVST) is a Top-Ranked Value Stock: Should You Buy?

October 9, 2026 | zacks.com

Here's Why Envista (NVST) is a Strong Growth Stock

October 8, 2026 | zacks.com

Envista (NYSE:NVST) Stock Rating Cut to Hold at Zacks Research

October 7, 2026 | marketbeat.com

Envista Schedules Third Quarter 2026 Earnings Call

October 6, 2026 | prnewswire.com

1 of Wall Street’s Favorite Stocks to Keep an Eye On and 2 We Ignore

October 2, 2026 | uk.finance.yahoo.com

Envista Holdings Corp (NVST)

October 1, 2026 | za.investing.com

Leaner Operations and Improving Dental Demand Position Envista Holdings Corp. (NVST) for Multi-Year Growth

October 1, 2026 | insidermonkey.com

Analysts Conflicted on These Healthcare Names: 4D Molecular Therapeutics (FDMT), Envista Holdings (NVST) and Regeneron (REGN)

September 30, 2026 | theglobeandmail.com

Noticias de Envista Holdings

September 29, 2026 | mx.investing.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BMRA, CUPR, NVST, and LUCYW Company Descriptions

Biomerica NASDAQ:BMRA

$1.72 -0.02 (-1.15%)

Closing price 10/30/2026 03:59 PM Eastern

Extended Trading

$1.72 +0.01 (+0.29%)

As of 10/30/2026 07:30 PM Eastern

Biomerica, Inc., a biomedical technology company, develops, patents, manufactures, and markets diagnostic and therapeutic products for the detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, nasal or fecal specimens from patients in the diagnosis of various diseases, food intolerances, and other medical complications; or to measure bacteria, hormones, antibodies, antigens, or other substances which may exist in the human body, stools, or blood in extremely small concentrations. It primarily sells its products for gastrointestinal diseases, food intolerances, and various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories. The company is also developing InFoods IBS, that uses a simple blood sample to identify patient-specific foods which may alleviate irritable bowel syndrome symptoms; and H. Pylori diagnostic test that indicates if a patient is infected with the H. Pylori bacteria. In addition, it develops products to indicate if a person has been infected by COVID-19. Biomerica, Inc. was incorporated in 1971 and is headquartered in Irvine, California.

Cuprina Holdings (Cayman) NASDAQ:CUPR

$1.75 -0.09 (-4.89%)

Closing price 10/30/2026 03:59 PM Eastern

Extended Trading

$1.78 +0.03 (+2.00%)

As of 10/30/2026 07:36 PM Eastern

We are a Singapore-based biomedical and biotechnology company that is dedicated to the development and commercialization of innovative products for the management of chronic wounds, as well as operating in the health and beauty sectors. Our expertise in biomedical research allows us to identify and utilize materials derived from natural sources to develop wound care products in the form of medical devices which meet international standards. We believe we will be able to build upon and leverage such expertise to develop innovative cosmeceutical products in the future. As of June 30, 2024, we manufactured and distributed a line of medical grade sterile blowfly larvae bio-dressing products marketed under the MEDIFLY brand name, or the MEDIFLY products. The MEDIFLY products are used as a biological debridement tool for chronic wounds, in a procedure known as Maggot Debridement Therapy, or MDT, which is an effective alternative to surgical debridement. In addition to our currently commercialized MEDIFLY products, we have two lines of chronic wound care products in our pipeline. Such lines of pipeline chronic wound care products include: . Collagen dressings, including sponges, particles and hydrogels utilizing bullfrog collagen derived from the valorization of abattoir waste streams of American bullfrogs (Lithobates catesbeianus); and . Products utilizing medical leeches for wound treatment. We currently expect development of such products to take place over the course of 2025 and 2026 and to become commercially available subject to regulatory approval. However, we may not be able to successfully develop the aforementioned pipeline products on the timeline currently envisioned, or at all, and even if we do, these products may not receive the necessary regulatory approvals from the authorities in the intended markets where we plan to introduce them. We believe what sets us apart is our focus on developing functionally specific chronic wound care products designed to address the major stages of wound healing process, from chronic to closure. Our chronic wound care products, including both our existing commercialized products and forthcoming products in our pipeline, are poised to benefit from escalating global market demand. This demand is primarily fueled by the demographic shift towards an aging population and the concurrent rise in comorbidities such as diabetes, obesity, cardiovascular ailments, and peripheral vascular diseases. We either self-develop our chronic wound care products or co-develop them through technology licensing agreements or research collaboration with a renowned research university. In June 2022, we were granted an exclusive license from NTUitive Pte. Ltd., a wholly owned subsidiary of Nanyang Technological University, to develop and commercialize a range of chronic wound care products using collagen derived from bullfrog skin. In addition, in August 2022, we entered into an industry research collaboration agreement with Nanyang Technological University, or, together with its subsidiaries, NTU, pursuant to which both parties agreed to jointly undertake a research project regarding the development and validation of bullfrog skin waste to generate collagen-based wound care products. We have been selling our MEDIFLY products primarily in Singapore since February 2020. In March 2023, our MEDIFLY products became commercially available in Hong Kong. Looking ahead, we have strategic plans in place for 2025 and 2026 to expand our sales and establish physical operations in several key regions, including the Middle East (in particular, the member states of the Gulf Cooperation Council, or GCC), and mainland China. These expansion initiatives will further enable us to cater to the growing demand for our products in these promising markets, cementing our position as a trusted player in the field of chronic wound care and treatment. For our cosmeceuticals business, we introduced three products in 2023, including a hydrating balm product, a muscle energy cream and a pain relief muscle patch. For our currently commercialized cosmeceutical products, we have commissioned original equipment manufacturers of skincare products to develop the formulation and manufacture the substantially finished and finished products. In addition, we plan to explore the possibility of developing a range of potential cosmeceutical product candidates incorporating bullfrog collagen with a view to making them commercially available between 2025 and 2028, subject to the progress of the relevant R&D work. We offer our chronic wound care products to both public and private hospitals and clinics, where patients can obtain them through prescription from a physician. Our customers primarily include major public and private hospitals and clinics in Singapore. Our commercialized cosmeceutical products can be purchased directly by individual customers through a variety of channels, including retailers and gyms in Singapore and other countries such as Malaysia and Australia, as well as online shopping platforms such as Shopee. Our commitment to quality is demonstrated by our attainment of ISO 13485:2016 standards for Quality Management Systems and Manufacturing Processes and Controls for our manufacturing facility located in Singapore in 2020. We are working towards obtaining compliance with 21 CFR Part 820, an integral component of the Current Good Manufacturing Practice, or CGMP, regulations, to secure FDA 510(k) clearance for our chronic wound care products, including both our existing commercialized products and forthcoming products in our pipeline. Our principal executive office is in Singapore.

Innovative Eyewear NASDAQ:LUCYW

$0.05 0.00 (-1.21%)

As of 10/30/2026 03:59 PM Eastern

Innovative Eyewear, Inc. develops and sells smart eyeglasses and sunglasses. The company's flagship product is Lucyd Lyte glasses that enable the wearer to listen to music, take and make calls, and use voice assistants and ChatGPT to perform various smartphone tasks hands-free. It also offers smart eyewear under the Lyte XL brand; and Nautica Powered by Lucyd smart eyewear collection and various branded accessories, including a power brick, cleaning cloth, and a slipcase adorned. In addition, the company provides Vyrb, a social media application that enables the user to receive and send posts through Lucyd Lyte smart glasses with an individual's voice; and Lucyd app for iOS and Android to provide voice access to ChatGPT in Lucyd eyewear. It sells its products through various e-commerce and retail channels. Innovative Eyewear, Inc. has a license agreement with Lucyd Ltd. The company was incorporated in 2019 and is headquartered in North Miami, Florida.

Envista NYSE:NVST

$23.48 -1.13 (-4.59%)

Closing price 10/30/2026 03:59 PM Eastern

Extended Trading

$23.50 +0.02 (+0.11%)

As of 10/30/2026 07:30 PM Eastern

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products. This segment also provides software packages, which include DTX Studio Implant; DTX Studio Lab; and DTX Studio Clinic, a software package offered with its imaging products. It offers its products under the Nobel Biocare, Alpha-Bio Tec, Implant Direct, Nobel Procera, Ormco, Spark, Orascoptic, Damon, Insignia, AOA brands. The Equipment & Consumables segment provides dental equipment and supplies, including digital imaging systems, software, and other visualization/magnification systems; endodontic systems and related products; restorative materials, rotary burs, impression materials, bonding agents, and cements; and infection prevention products. This segment offers its products under the Dexis, DTX Studio, Kerr, Metrex, Total Care, Pentron, Optibond, Harmonize, Sonicfill, Sybron Endo, and CaviWipes to dental offices, clinics, and hospitals. Envista Holdings Corporation was incorporated in 2018 and is headquartered in Brea, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BMRA, CUPR, NVST, and LUCYW Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BMRA, CUPR, NVST, and LUCYW Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BMRA, CUPR, NVST, and LUCYW Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

BMRA, CUPR, NVST, and LUCYW Company Descriptions

Biomerica NASDAQ:BMRA

Cuprina Holdings (Cayman) NASDAQ:CUPR

Innovative Eyewear NASDAQ:LUCYW

Envista NYSE:NVST

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BMRA, CUPR, NVST, and LUCYW Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BMRA, CUPR, NVST, and LUCYW Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BMRA, CUPR, NVST, and LUCYW Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

BMRA, CUPR, NVST, and LUCYW Company Descriptions

Biomerica NASDAQ:BMRA

Cuprina Holdings (Cayman) NASDAQ:CUPR

Innovative Eyewear NASDAQ:LUCYW

Envista NYSE:NVST

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools